Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Genprex’s (GNPX) research collaborators at a major cancer research center in Houston, Texas have published a new study which used the company’s ...

"At Edible Garden, sustainability is more than just a goal—it is a core principle that guides everything we do," said Jim Kras, CEO of Edible Garden. "The introduction of our curb-side recyclable pot ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Belvidere-based Edible Garden is bringing something new to the table. After a successful pilot production, the hydroponic ...

In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...